rosiglitazone has been researched along with gw 590735 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Endo, T; Kanda, T; Nakamura, H; Sakuma, S; Yamakawa, T; Yamasaki, S | 2 |
| Dou, XZ; Duerfeldt, AS; Ma, JX; Nath, D; Shin, Y | 1 |
| Bourne, PC; Dou, X; Duerfeldt, AS; Ma, JX; Nath, D; Nurmemmedov, E; Shin, H | 1 |
4 other study(ies) available for rosiglitazone and gw 590735
| Article | Year |
|---|---|
Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation.
Topics: Animals; Brain; Cell Differentiation; Humans; Isoxazoles; Multiple Sclerosis; Oligodendroglia; Oxazoles; PPAR delta; Rats; Transcriptional Activation | 2011 |
Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.
Topics: Animals; Cell Differentiation; Cell Line; Cells, Cultured; Cerebral Cortex; Humans; Isoxazoles; Oligodendroglia; PPAR delta; Rats; Rats, Wistar | 2011 |
Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARα selective agonists: New leads for oculovascular conditions.
Topics: Dose-Response Relationship, Drug; Eye Diseases; Humans; Ligands; Models, Molecular; Molecular Structure; PPAR alpha; Quinolines; Structure-Activity Relationship; Vascular Diseases | 2018 |
Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders.
Topics: Animals; Benzylamines; Capillary Permeability; Cell Line; Diabetic Retinopathy; Disease Models, Animal; Drug Design; Drug Discovery; Humans; PPAR alpha; Rats; Retinal Diseases; Streptozocin | 2020 |